Evommune (EVMN) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Sol-Gel Technologies is the larger company by market cap ($235.5 million vs $225.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | SLGL |
|---|---|---|
| Share price | $6.22 | $71.95 |
| Market cap | $225.74M | $235.55M |
| 1-day change | -5.90% | -4.88% |
| YTD return | -63.67% | +70.73% |
| 1-year return | — | +75.52% |
| 5-year return | — | -22.85% |
| EPS (TTM) | $-3.75 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $97.97 |
| 52-week low | $6.08 | $28.81 |
| Distance from 52-week high | -81.27% | -26.56% |
| Average volume | 682.82K | 55.46K |
| Shares outstanding | 36.29M | 3.27M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
EVMN vs SLGL FAQ
Which is bigger, Evommune or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $235.55M compared with $225.74M for Evommune (EVMN).
Are Evommune and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.